Cytokinetics recently announced that MYQORZO (aficamten), a cardiac myosin inhibitor for adults with symptomatic obstructive hypertrophic cardiomyopathy, is now commercially available in the U.S. via ...
The blog recommended that users learn to train their own AI models by downloading the Harry Potter dataset and then uploading text files to Azure Blob Storage. It included example models based on a ...
Credit: Getty Images HCM is a genetic disease, usually caused by mutations in sarcomere proteins such as myosin, actin, tropomyosin, and myosin-binding protein C. Hypertrophic cardiomyopathy (HCM) ...
Hosted on MSN
Bristol Myers, Gilead, J&J, Novartis win favorable FDA label updates for cell therapies
The U.S. Food and Drug Administration (FDA) has approved several label updates for CAR-T cell therapies marketed by Bristol Myers Squibb (NYSE:BMY), Gilead Sciences (NASDAQ:GILD), J&J (NYSE:JNJ), and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results